Recent Company News

• 08:04 AM ET Jan 30, 2026
  

  Kazia Therapeutics announces preclinical and translational data for nuclear PD-L1 degrader (NDL2) ($6.10, 0.00)

• 08:00 AM ET Jan 30, 2026
  

  Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

• 08:04 AM ET Jan 27, 2026
  

  Kazia Therapeutics reports preliminary clinical responses in ongoing Phase 1B study of paxalisib in late-stage metastatic triple-negative breast cancer ($7.93, 0.00)

• 08:00 AM ET Jan 27, 2026
  

  Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

• 01:05 PM ET Jan 08, 2026
  

  Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

• 12:35 PM ET Jan 08, 2026
  

  How $594B in Precision Tech is Cracking the Metastatic Cancer Code

• 05:49 PM ET Nov 18, 2025
  

  StreetAccount Summary - After-hours trading update

• 04:39 PM ET Nov 18, 2025
  

  StreetAccount Summary - After-hours trading

• 04:17 PM ET Nov 18, 2025
  

  Kazia Therapeutics achieves initial iCR (Immune-Complete Response) in metastatic TNBC ($5.76, 0.00)

• 07:17 AM ET Oct 27, 2025
  

  Kazia Therapeutics to request FDA Type C meeting to discuss overall survival data in GBM treated with paxalisib and potential NDA filing ($6.98, 0.00)